RecruitingPhase 2NCT07391241

A Phase 2 Study to Evaluate the Efficacy and Safety of Pudafensine in Vulvodynia (Provoked Vestibulodynia)

A Randomised, Double-blind, Placebo-controlled, 4-way Cross-over Trial Studying the Efficacy and Safety of Single Dose Administration of Pudafensine in Vulvodynia (Provoked Vestibulodynia).


Sponsor

Initiator Pharma

Enrollment

24 participants

Start Date

Dec 17, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The study (IP2015CS05) is a randomised, double-blind, placebo-controlled, 4-way cross-over trial studying the efficacy and safety of single dose administration of pudafensine in vulvodynia (provoked vestibulodynia) patients.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 65 Years

Inclusion Criteria1

  • Participant with vulvodynia (provoked vestibulodynia).

Exclusion Criteria13

  • Women with vulvar pain caused by a specific disorder:
  • Infectious (e.g. recurrent candidiasis, herpes).
  • Inflammatory (e.g. lichen sclerosus, lichen planus, immunobullous disorders).
  • Neoplastic (e.g. Paget disease, squamous cell carcinoma).
  • Neurologic (e.g. postherpetic neuralgia, nerve compression or injury, neuroma).
  • Trauma (e.g. female genital cutting, obstetrical).
  • Iatrogenic (e.g. postoperative, chemotherapy, radiation).
  • Hormonal deficiencies (e.g. genitourinary syndrome of menopause (vulvovaginal atrophy), lactational amenorrhea).
  • History or current diagnosis of significant pelvic floor dysfunction.
  • Co-morbid pelvic pain conditions including pain due to pelvic fractures, pelvic girdle pain or post-partum pelvic pain (to avoid confounding pain outcomes).
  • History or current diagnosis of pelvic inflammatory disease.
  • History or current diagnosis of endometriosis.
  • History or current diagnosis of interstitial cystitis.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPudafensine

Pudafensine


Locations(1)

MAC

Blackpool, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07391241


Related Trials